Dual and Triple Immunomodulatory Protocols for Recurrent Implantation Failure in Endometriosis & Adenomyosis
- Gynec Research
- 6–8 minutes
- Knowledge Centre
- International Journal of Clinical Obstetrics and Gynaecology
Recurrent implantation failure (RIF) remains a significant challenge in assisted reproductive technology, particularly in patients with underlying endometriosis and adenomyosis. The condition can involve multiple contributing factors, including altered endometrial receptivity, inflammatory and immune mechanisms, and abnormal uterine contractility.
This retrospective observational study explored a protocol-based immunomodulatory approach in patients with confirmed endometriosis and a history of repeated implantation failure. The study included 21 patients who had experienced three or more failed good-quality blastocyst transfers. Patients were treated between July and December 2025 at a tertiary fertility centre.
The treatment approach was differentiated according to the patient’s clinical presentation. Dual therapy, consisting of Thymosin alpha-1 (Thymovian) and Intralipid (Improvian), was used in patients with recurrent implantation failure and endometriosis without associated adenomyosis. For patients with associated adenomyosis/endometriosis, Atosiban (Atosivian) was added to the dual regimen to form a triple-therapy protocol, with the objective of addressing the potential contribution of increased uterine contractility.
Key Findings
The study reported an overall biochemical pregnancy rate of 52.4% (11/21) and an ongoing clinical pregnancy rate of 47.6% (10/21). Within the treatment groups, the reported success rate was 60.0% with dual therapy and 44.4% with triple therapy.
The study also reported one early pregnancy loss among the 11 biochemical pregnancies and one ectopic pregnancy. Regarding safety, one patient experienced a mild, transient episode of skin rash and itching during Intralipid administration. Following this event, sensitivity testing was introduced for subsequent patients, and no further allergic reactions were reported.
The authors suggest that the findings provide preliminary evidence supporting further investigation of protocol-based immunomodulation in selected patients with RIF and confirmed endometriosis, while emphasizing that larger and randomized controlled studies are required before definitive conclusions can be drawn.
Why This Research Matters
The study offers an interesting perspective on the use of different immunomodulatory strategies according to the clinical characteristics of patients experiencing recurrent implantation failure. By distinguishing between dual therapy for RIF without adenomyosis and triple therapy for RIF with adenomyosis/endometriosis, the research explores both immune-related and potential mechanical factors involved in implantation.
Read the complete research article to explore the study methodology, treatment protocols, patient characteristics, pregnancy outcomes, safety observations and detailed discussion.
Research Article
Pahlajani NM, Janardhanan S. Dual and Triple Immunomodulatory Protocols for Recurrent Implantation Failure in Endometriosis and Adenomyosis: Clinical Outcomes and Safety Profile. International Journal of Clinical Obstetrics and Gynaecology. 2026;10(2):1560–1567. DOI: 10.33545/gynae.2026.v10.i2t.2222.

